The CEO received total compensation of approximately $5.1 million — including $4.065 million in stock option awards — at a company with a $300 million market cap that has lost 36.9% of its value over three years while the XBI (SPDR S&P Biotech ETF) gained 57.5%, a gap of 94.4 percentage points that represents severe underperformance for shareholders. All equity grants are time-vesting stock options with no disclosed performance conditions, meaning executives receive the same equity vesting whether the stock goes up or down — this is effectively fixed pay dressed up as variable pay and fails the policy's requirement that incentive pay be tied to meaningful performance outcomes. The combination of above-benchmark pay levels for a sub-$500M biotech CEO, the absence of any performance-based vesting conditions, and the stark disconnect between executive compensation and the shareholder experience warrants a NO vote.

CohnReznick LLP has served as Compass's auditor since 2020 (approximately 6 years), well below the 25-year tenure threshold that would raise independence concerns; the non-audit fees (audit-related fees of $129,570 plus tax fees of $68,829, totaling $198,399) represent about 64% of the core audit fee of $310,800, which exceeds the 50% threshold — however, audit-related fees here consist of SEC registration statement services that are closely tied to the company's capital-raising activities rather than advisory or consulting work that could compromise independence, and at a $300M market cap company CohnReznick is an appropriate-sized national firm; on balance the non-audit ratio is a yellow flag but not sufficient on its own to override a FOR given the nature of the fees and the firm's fit for the company's size.